Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs).
Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
We are building a pipeline of ADCs centred on:
• PermaLink® – proprietary conjugation chemistry for improved ADC stability
• Novel ultra-potent toxins for improved tumour killing
• Novel antibodies targeted towards well-selected antigens associated
primarily with solid tumours
We are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours such as lung, ovarian, cervix, pancreatic and colorectal.
Our first wave ADC programmes include antibodies with proven premise in ADC formats and novel DNA damaging payloads.
We are working with leading research institutions in the US and Europe to develop exciting new therapies for the future. We are flexible in our approach to collaboration and welcome discussions with research groups who have novel ADC-relevant programmes.
We have developed a series of high-value ADC assets, which are available for collaborative research and license.
Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
We are building a pipeline of ADCs centred on:
• PermaLink® – proprietary conjugation chemistry for improved ADC stability
• Novel ultra-potent toxins for improved tumour killing
• Novel antibodies targeted towards well-selected antigens associated
primarily with solid tumours
We are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours such as lung, ovarian, cervix, pancreatic and colorectal.
Our first wave ADC programmes include antibodies with proven premise in ADC formats and novel DNA damaging payloads.
We are working with leading research institutions in the US and Europe to develop exciting new therapies for the future. We are flexible in our approach to collaboration and welcome discussions with research groups who have novel ADC-relevant programmes.
We have developed a series of high-value ADC assets, which are available for collaborative research and license.
Location: United Kingdom
Employees: 11-50
Total raised: $47M
Investors 2
| Date | Name | Website |
| 20.06.2023 | Premier Pa... | premierpar... |
| - | Mirae Asse... | vc.miraeas... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.06.2021 | - | $47M | - |
Mentions in press and media 11
| Date | Title | Description |
| 06.01.2026 | Iksuda to Present Preliminary Analysis of Oesophageal Cancer Data From Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium | Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of early analyses of activity in patients with oesophageal cancer during its Phase 1 study of IKS014, a human ep... |
| 22.06.2021 | IP : Iksuda Therapeutics Ltd - LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates | Expanded agreement grants Iksuda access to Legochem Biosciences' next generation ADC platform for up to six targets Iksuda also gains access to LegoChem Biosciences' new payload, supplementing the tumour-activated payloads accessed in 2020 ... |
| 22.06.2021 | LegoChem Biosciences and Iksuda Therapeutics expand licence agreement for development of antibody-drug conjugates | LegoChem Biosciences and Iksuda Therapeutics expand licence agreement for development of antibody-drug conjugates 22-06-2021 Newcastle, UK, 22 June, 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (A... |
| 08.06.2021 | IP GROUP PLC IP : Iksuda Therapeutics Ltd - Closes $47 million financing round | • Funding to accelerate clinical progression of Iksuda's pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need • Investment round led by Korean-based Mirae Asset Capital and Celltrion Newcastle, UK, ... |
| 08.06.2021 | IP : Iksuda Therapeutics Ltd - Closes $47 million financing round | • Funding to accelerate clinical progression of Iksuda's pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need • Investment round led by Korean-based Mirae Asset Capital and Celltrion Newcastle, UK, ... |
| 08.06.2021 | Iksuda Therapeutics Raises $47M in Funding | Iksuda Therapeutics, a Newcastle UK-based company focused on developing antibody drug conjugates (ADCs), raised $47M in funding. The round was co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The company i... |
| 07.06.2021 | Iksuda Therapeutics closes $47 million financing round | Newcastle, UK, 07 June 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, ... |
| 07.06.2021 | Iksuda Therapeutics : Closes $47 Million Financing Round | Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asse... |
| 07.06.2021 | Iksuda Therapeutics closes $47 million financing round | Iksuda Therapeutics closes $47 million financing round 07-06-2021 Newcastle, UK, 07 June 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has c... |
| 07.06.2021 | Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic | Iksuda Therapeutics has raised $47 million to take a CD19-targeted antibody-drug conjugate (ADC) into the clinic. The British biotech has ceded a big head start to CD19 ADC leader ADC Therapeutics but thinks it can come from behind by deliv... |
Show more